Suven Life Sciences Limited

Suven Life Sciences Limited (SUVEN) is a small-cap Healthcare company valued at ₹8,583 crore operating in Healthcare Research, Analytics & Technology on the NSE and BSE.

Recent price move

Suven Life Sciences Limited last traded at ₹305.5, modestly up 1.75% on the day.

Recent developments

On 2026-08-31, promoter holding was reported at 65.47%, showing no change from the previous quarter. The company reported a net loss of ₹276 crore for the latest financial year, reflecting continued losses.

Financial performance

The company's business is deteriorating, with annual net profit worsening from a loss of ₹161 crore to ₹276 crore. Revenue remained flat at ₹7 crore, but the latest quarter saw revenue rise 78.5% year-over-year to ₹4 crore, while the net loss widened from ₹52 crore to ₹128 crore.

Valuation multiples

A price-to-earnings ratio is not meaningful here because the company is loss-making; the stock trades at 14.92 times book value.

Things to watch

The company's net profit margin has deteriorated to -3,942.9%, a drop of 1,642.9 percentage points from the prior year. The net loss widened significantly in the latest quarter, and the stock is 23.6% below its 52-week high. Return on equity and return on capital employed are both negative, indicating poor profitability.

Where it stands

The company continues to report substantial losses, with the latest quarter's net loss reaching ₹128 crore. The stock is 23.6% below its 52-week high, and the net profit margin has worsened to -3,942.9%. The business is struggling with profitability and growth.

Summarised by DocStoX's model on 2026-10-03 from company filings, exchange data and news. This is a factual summary, not a rating or a recommendation. Informational only, not investment advice. Consult a SEBI-registered adviser before investing.